Literature DB >> 7999860

Peritoneal equilibration test in Chinese patients.

F K Wong1, C S Li, C K Mak, K F Chau, K S Choi.   

Abstract

Since the introduction of the peritoneal equilibration test (PET) by Twardowski in 1987, it became a widely accepted test that provided useful prognostic information on continuous ambulatory peritoneal dialysis (CAPD). It had been shown to be a readily reproducible test if the standard procedure was followed. Although there was wide interpersonal difference in the test results, the mean and range (and standard deviation, SD) were remarkably similar as suggested by Davies et al. in 1993 (3). We had performed PET on our CAPD patients for a few years, and all along we used the reference range established by Twardowski to classify our patients into High, High average, Low average, and Low transporters because no reference range had ever been established in Chinese. The aim of this study was to define the normal mean and range of the PET results in Chinese CAPD patients. We analyzed 100 PET results from 100 Chinese CAPD patients. The mean +/- (SD) of the ratio of dialysate/plasma of creatinine and glucose at four-hour dwell times were 0.71 (0.15) and 0.37 (0.12), respectively. There was a significant difference in the dialysate/plasma ratio of creatinine (p < 0.01) while that of glucose was similar when compared with those found by Twardowski. There was no difference in the solute transfer in diabetic and nondiabetic patients. We concluded that the creatinine clearance of the peritoneal membrane in Chinese CAPD patients was higher than the previously reported result in North American patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7999860

Source DB:  PubMed          Journal:  Adv Perit Dial        ISSN: 1197-8554


  1 in total

1.  Dialysate glucose response phenotypes during peritoneal equilibration test and their association with cardiovascular death: A cohort study.

Authors:  Zheng Wang; Dahai Yu; Yamei Cai; Shuang Ma; Bin Zhao; Zhanzheng Zhao; David Simmons
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.